

ORIGINAL ARTICLE

Formulation development of anti-stress compressed lozenges using a fractional factorial Latin cube design and ANOVA approach

Vývoj formulace antistresových pastilek připravených lisováním s využitím frakčního faktoriálního designu Latin cube a přístupu ANOVA

Oleksii Yakovenko • Tetiana Kolisnyk • Olena Ruban • Natalia Fil

Received February 28, 2021 / Accepted April 13, 2021

Summary

The aim of this work was to develop anti-stress compressed lozenges containing 100 mg of glycine and 250 mg of magnesium citrate obtained by the direct compression method. To choose optimal excipient composition providing the sufficient pharmacotechnical properties of the tablet blend, mechanical strength of tablets and non-disintegrating, slow-dissolving behavior of compressed lozenges during sucking, 27 experimental formulations according to fractional factorial Latin cube design were prepared and tested. The excipients used in the study were: Mannogem® EZ, Cellactose® 80 and GalenIQ™ 721 (fillers); Plasdone™ S-630, Kollidon® 90 F and Avicel® PH-101 (dry binders); Metolose® 90SH-4000SR and guar gum (gel-forming binders); PRUV®, Neusilin® US2, and Compritol® 888 CG ATO (antifricition excipients). The following parameters were investigated as responses: bulk density, Carr's index, friability, resistance to crushing, and *in vitro* disintegration time. ANOVA approach was applied for statistical processing, which allowed to reveal the individual effects of each excipient and several interaction effects observed for the excipient amounts used in this study. Isomalt (GalenIQ™ 721), copovidone (Plasdone™ S-630), and

glyceryl behenate (Compritol® 888 CG ATO) were selected to be incorporated in the final formulation of compressed lozenges.

Key words: compressed lozenges • glycine, magnesium citrate • stress-protective activity • formulation development • design of experiment • analysis of variance

Souhrn

Cílem práce bylo vyvinout antistresové pastilky obsahující 100 mg glycinu a 250 mg magnesium-citrátu získané metodou přímého lisování. Aby bylo možné zvolit optimální složení pomocných látek poskytující dostatečné kvalitativní vlastnosti tabletoviny, mechanickou pevnost tablet a jejich odolnost a pomalé rozpouštění v ústech, bylo připraveno a testováno 27 experimentálních formulací podle frakčního faktoriálního designu latinských čtverců. Pomocné látky použité ve studii byly: Mannogem® EZ, Cellactose® 80 a GalenIQ™ 721 (plniva); Plasdone™ S-630, Kollidon® 90 F a Avicel® PH-101 (suchá pojiva); Metolose® 90SH-4000SR a klovatina guar (gelotvorné látky); PRUV®, Neusilin® US2 a Compritol® 888 CG ATO (antifrakční pomocné látky). Byly zkoumány následující parametry: sypaná hustota, Carrův index, oděr, pevnost a doba rozpadavosti *in vitro*. Pro statistické zpracování byl použit přístup ANOVA, který umožnil odhalit jednotlivé vlivy každé použité pomocné látky a několik interakčních účinků pozorovaných u množství excipientů použitých v této studii. Isomalt (GalenIQ™ 721), kopovidon (Plasdone™ S-630) a glycerylbehenát (Compritol® 888 CG ATO) byly vybrány pro začlenění do konečné formulace lisovaných pastilek.

Klíčová slova: lisované pastilky • glycin • magnesium-citrát • aktivita chránící proti stresu • vývoj formulace • návrh experimentu • analýza rozptylu

O. Yakovenko • Tetiana Kolisnyk (✉) • O. Ruban
Department of Industrial Technology of Drugs
National University of Pharmacy
Valentynivska str. 4, 61168 Kharkiv, Ukraine
e-mail: kolisnyktyana@gmail.com

N. Fil
Department of Automation and Computer-Integrated Technologies
Kharkiv National Automobile and Highway University, Kharkiv, Ukraine

Introduction

Oromucosal administration of drugs offers several advantages over the traditional oral route. One of the most important among them is the ability of a drug to be rapidly absorbed through the oral mucosa and directly enter the systemic circulation, avoiding in such a way (at least, partially) the first-pass metabolism in the gastrointestinal tract (GIT)¹⁾.

Compressed lozenges are one of three types of oromucosal tablets, distinguished by the European Pharmacopoeia (Ph. Eur.)²⁾. Unlike the other two types, which are sublingual tablets and buccal tablets, compressed lozenges may be intended for systemic or local action (in the latter case, e.g., for the treatment of cold-related throat conditions). The principal difference of compressed lozenges from the oromucosal tablets mentioned above involves the oral cavity site, where the drug delivery should occur. In a few words, sublingual tablets are applied precisely under the tongue and buccal tablets to the cheeks' inner lining, whereas compressed lozenges are aimed to be sucked. Hence, they deliver a drug to various regions of the oral cavity. These administration features are reasoned by the oral epithelium properties, and they determine certain specific requirements for each type of tablets. For instance, both sublingual and buccal epithelia are non-keratinized. However, the first one is regarded as the most efficient place in the oral cavity for drug absorption since it is 2.5–6 times thinner than the buccal one. At the same time, the sublingual area is relatively small and constantly undergoes washing by the saliva and movements of the tongue^{3–5)}. Therefore, sublingual tablets are only suitable for low-dose drugs (usually, not more than 10 mg per dosage unit), which can rapidly dissolve in the saliva and then be immediately absorbed. Accordingly, these tablets must quickly disintegrate on contact with small amounts of liquid (i.e., saliva) to facilitate drug dissolution. Otherwise, most of the drug is flowed down with the saliva and ingested in the GIT. In turn, the buccal mucosa is much less affected by the saliva flow or by the tongue, allowing buccal preparations to retain in contact with mucosal lining for a longer period. To extend the retention time, mucoadhesive properties are preferred for the buccal preparations, including buccal tablets^{6, 7)}.

As to compressed lozenges, the necessity of sucking them requires this type of tablets to be non-disintegrating and slow-dissolving, which is usually achieved through high hardness and/or the addition of certain binders such as tragacanth, methylcellulose, etc.^{8, 9)}. In the case of systemic preparations, sucking may help to distribute the dose of the drug throughout the mouth, providing absorption of it by different oral regions; for this purpose, the drug's release rate should be slow enough to avoid as much as possible its swallowing. If such a task is solved, then drugs with a higher dose (as compared to sublingual tablets) may

also be used in oromucosal delivery systems. It should also be noted that there is an additional effect of sucking as a way of taking drugs, such as physiological soothing. As it was reported, suckling is linked with oxytocin release in infants through activation of touch receptors in the oral cavity^{10, 11)}. This hormone, mostly recognized as involved in labor and breastfeeding, has been reported to reduce fear and anxiety and produce antidepressant-like effect^{12, 13)}. In light of this, it is supposed that smoking addiction in adults is provoked not only by nicotine but also oxytocin release effects when sucking on cigarettes¹¹⁾. This explains the usefulness of candy lozenges in smoking cessation, as well as the rationale for incorporation of nicotine replacement products in the form of compressed lozenges or chewing gums (e.g., Nicorette® and Nicotinell®). From this point of view, in such preparations, the pharmacological effect of nicotine is augmented by the physiological calming action of sucking or mastication.

Therefore, we consider compressed lozenges as an appropriate dosage form to develop the anti-stress formulation containing glycine and magnesium citrate as active pharmaceutical ingredients (APIs). Glycine is the simplest amino acid representing the major inhibitory neurotransmitter in the adult central neural system (CNS)^{14, 15)}. There are scientific reports on the efficacy of glycine in improving sleep quality, its neuroprotective effects for the therapy of acute ischemic stroke, as well as positive action in the animal models of hypertension and cognitive function assessment, etc.^{16–21)}. Glycine in the form of sublingual tablets (100 mg per tablet) is an approved medicinal product in Russia, Ukraine, Belarus, and some other countries. A recent study in rodents has confirmed glycine anti-anxiety effect; however, it was also shown that the stress-protective action of glycine can be enhanced by combining it with magnesium citrate²²⁾. The latter is a soluble organic salt of magnesium, a deficiency of which is known to be related to stress reactions^{23, 24)}. It is worth noting that, unlike most drug substances, both glycine and magnesium citrate do not have a bitter, unpleasant taste (glycine is sweetish, and magnesium citrate is slightly acidic), which makes them favorable candidates for oromucosal preparations.

Thus, the present study was devoted to the formulation development of compressed lozenges containing glycine and magnesium citrate. Design of experiment (DoE) methodology and analysis of variance (ANOVA) approach were applied to select optimal excipients that allow achieving best manufacturability of the finished product (in terms of flowability and compressibility of tablet blend), as well as its pharmaco-technical characteristics – standard for all tablets (absence of appearance defects, required mechanical resistance) and specific for this type of tablets (non-disintegrating, slow-dissolving behavior).

Experimental part

Materials

The following substances were used to obtain experimental formulations of compressed lozenges: glycine and magnesium citrate (PureBulk Inc, USA), spray-dried mannitol (Mannogem® EZ, SPI Pharma, USA), a co-spray dried mixture of the alpha-lactose monohydrate and microcrystalline cellulose (Cellactose® 80, Meggle G.m.b.H., Germany), spherical isomalt for direct compression (GalenIQ™ 721, BENEOPalatinit GmbH, Germany), N-vinyl-2-pyrrolidone and vinyl acetate (Plasdone™ S-630 copovidone, Ashland Inc.), high-molecular weight povidone (Kollidon® 90 F, BASF SE, Germany), microcrystalline cellulose (Avicel® PH-101, FMC Corporation, USA), hypromellose (Metolose 90SH-4000SR, Shin-Etsu Chemical Co. Ltd, Japan), guar gum (Sigma Aldrich, USA), sodium stearyl fumarate (PRUV®, JRS Pharma GmbH & Co. KG, Germany), magnesium aluminometasilicate (Neusilin® US2, Fuji Chemical Industry Co. Ltd., Japan), glyceryl behenate (Compritol® 888 CG ATO, Gattefossé, France).

Experimental design

Latin cube fractional factorial design, which involves the investigation of four factors, each varying at three levels with 2 complete replications, was utilized in this study. Factors, levels, and responses according to experimental design are listed in Table 1.

Preparation of compressed lozenges

Experimental formulations of compressed lozenges were prepared by the direct compression method. For this purpose, glycine and magnesium citrate (100 and 250 mg per tablet, respectively) were sieved through a sieve with a pore diameter of 0.2 mm and then thoroughly mixed with excipients corresponding to each formulation using a mortar and a pestle. After evaluating the bulk properties, all powder blends were directly compressed into flat-faced cylindrical tablets with a diameter of 11 mm and a nominal weight of

500 mg using a laboratory single-punch tablet machine. All formulations were obtained in two replicates.

Evaluation of the bulk properties of the powder blends

Bulk properties of each formulation were assessed by the bulk density and Carr's index according to Ph. Eur. 10.0 chapters 2.9.34 "Bulk density and tapped density of powders" and 2.9.36 "Powder flow" ²⁾. Pharma Test tap density tester (model PT-TD1, Germany) was used to determine the bulk and tapped density values, and based on these data, Carr's index was calculated. All measurements were repeated 3 times.

Evaluation of the prepared compressed lozenges

The prepared compressed lozenges were evaluated by their friability, resistance to crushing, and time of disintegration (dissolution).

Friability and resistance to crushing determinations were carried out by pharmacopoeial tests described in chapters 2.9.7 "Friability of uncoated tablets" and 2.9.8 "Resistance to crushing of tablets" using a PTF 20E friability apparatus (Pharma Test, Germany) and a Monsanto hardness tester (Campbell Elec., India), respectively²⁾.

To assess the behavior of the compressed lozenges in a liquid medium (whether it is disintegrating or not and how much time it takes), the disintegration test was performed in accordance with Ph.Eur. chapter 2.9.1 "Disintegration of tablets and capsules" using BJ-2 disintegration apparatus (MINHUA Pharmaceutical Machinery Co., Ltd., China) and purified water as a disintegration medium²⁾.

All tablet evaluation measurements were repeated 6 times.

In vivo sucking time of compressed lozenges

For estimation of *in vivo* sucking time of the formulations selected by statistical analysis, six healthy volunteers were asked just to suck each sample of compressed lozenges until it completely dissolves without treating

Table 1. Factors, levels, and responses according to experimental design

Factors	Levels	Responses
A – fillers (up to the tablet weight of 500 mg for all levels)	a ₁ – Mannogem® EZ	y ₁₁ , y ₁₂ – bulk density, g/cm ³ ; y ₂₁ , y ₂₂ – Carr's index, %; y ₃₁ , y ₃₂ – friability, %; y ₄₁ , y ₄₂ – resistance to crushing, N;
	a ₂ – Cellactose® 80	
	a ₃ – GalenIQ™ 721	
B – dry binder (10.0% of the tablet weight for all levels)	b ₁ – Plasdone™ S-630	y ₅₁ , y ₅₂ – time of disintegration/dissolution, min
	b ₂ – Kollidon® 90 F	
	b ₃ – Avicel® PH-101	
C – gel-forming binder	c ₁ – absence of such binder	
	c ₂ – Metolose® 90SH-4000SR (3.0 % of the tablet weight)	
	c ₃ – guar gum (3.0 % of the tablet weight)	
D – lubricant/glidant	d ₁ – PRUV® (1.0 % of the tablet weight)	
	d ₂ – Neusilin® US2 (3.0 % of the tablet weight)	
	d ₃ – Compritol® 888 CG ATO (2.0 % of the tablet weight)	

it by the tongue and the time of sucking was registered. Volunteers also were asked about their subjective perceptions while sucking (concerning taste and aftertaste assessment).

Statistical processing and interpretation of the experimental data

The experimentally determined responses from 27 formulations were processed by the ANOVA approach. All calculations were conducted using Microsoft Excel 2010 software. Every set of the studied responses was processed by the same algorithm as described below²⁵.

At the first step the variances (s^2) were estimated for each replicate pair of 27 experiments and the variance homogeneity assumption was checked by Cochran variance outlier test. To do this, the experimental Cochran's C value (C_{exp}) was determined as and then compared with its tabulated critical value at $\alpha = 0.05$ (total number of experimental formulations (N) is 27, and degrees of freedom (f) is equal to the number of replications (r) minus 1) ($C_{0.05}$). In case Cochran's C value is lower than the critical value, the assumption of variance homogeneity is met, and ANOVA may be performed.

Briefly, the ANOVA approach involved calculating the sums of squares (SS), the mean squares (MS), and the variance ratios. The last ones are commonly called the F statistic values and estimated as the ratios of variance due to the effect of factor and variance due to the error term. F value is used to evaluate the significance of the factor (or interaction of several factors) with respect to the variance of all of the factors included in the error term. A calculated F value (F_{exp}) is compared with a tabulated F-value at a given statistical level of significance and degrees of freedom ($F_{0.05}$). The factor (or interaction of the factors) is considered to contribute to the sum of squares (within the confidence level) if F_{exp} is greater than the value from standard F-tables.

ANOVA calculations are carried out in the following sequence. The results by each level of the factors **A**, **B**, **C**, and **D** (A_i , B_j , C_k , and D_l , respectively) are summed up. Then SS are calculated by the formulas [1–5]:

$$SS_T = \sum_1^{n^3r} y_{ijkl}^2 - \frac{(\sum_1^{n^3r} y_{ijkl})^2}{n^3r}, \quad [1]$$

$$SS_A = \frac{\sum_1^n A_i^2}{n^2r} - \frac{(\sum_1^{n^3r} y_{ijkl})^2}{n^3r}, \quad [2]$$

$$SS_B = \frac{\sum_1^n B_j^2}{n^2r} - \frac{(\sum_1^{n^3r} y_{ijkl})^2}{n^3r}, \quad [3]$$

$$SS_C = \frac{\sum_1^n C_k^2}{n^2r} - \frac{(\sum_1^{n^3r} y_{ijkl})^2}{n^3r}, \quad [4]$$

$$SS_D = \frac{\sum_1^n D_l^2}{n^2r} - \frac{(\sum_1^{n^3r} y_{ijkl})^2}{n^3r}, \quad [5]$$

where SS_T – the total squared deviation from the mean value of the data; SS_A , SS_B , SS_C , and SS_D are the sums of squared deviations by the levels from the mean for factors **A**, **B**, **C**, and **D**, respectively; y_{ijkl} – result, obtained in testing the formulation which is the

combination of i^{th} , j^{th} , k^{th} , and l^{th} levels of factors **A**, **B**, **C**, and **D**, respectively; n – number of levels; r – number of replications.

Latin cube design with replicate experiments gives the possibility to evaluate the effect of paired factor interactions on the responses. To do this, the effects of at least one of four factors on the rest should be slighted. In this work factor **C** (gel-forming binder) was considered as a blocking or nuisance factor (i.e., a factor that has some effect on the responses but is of no interest to the experimenter). This consideration is argued by the fact that the only purpose of these excipients to be included in the formulation was assumed to slow down the disintegration of compressed lozenges in the liquid medium; however, the best results were obtained in the absence of a gel-forming binder (see Results and Discussion sections). Therefore for all responses including disintegration time factor **C** was assumed to be negligible. SS for the paired interactions **AB**, **AD**, **BD**, and triple interaction **ABD** are determined using the formulas [6–9]:

$$SS_{AB} = \frac{\sum_1^{n^2} (A_i B_j)^2}{nr} - SS_A - SS_B - \frac{(\sum_1^{n^3r} y_{ijkl})^2}{n^3r}, \quad [6]$$

$$SS_{AD} = \frac{\sum_1^{n^2} (A_i D_l)^2}{nr} - SS_A - SS_D - \frac{(\sum_1^{n^3r} y_{ijkl})^2}{n^3r}, \quad [7]$$

$$SS_{BD} = \frac{\sum_1^{n^2} (B_j D_l)^2}{nr} - SS_B - SS_D - \frac{(\sum_1^{n^3r} y_{ijkl})^2}{n^3r}, \quad [8]$$

$$SS_{ABD} = \frac{\sum_1^{n^3} (A_i B_j D_l)^2}{r} - \frac{(\sum_1^{n^3r} y_{ijkl})^2}{n^2r} - SS_A - SS_B - SS_D \quad [9]$$

where $A_i B_j$, $A_i D_l$, $B_j D_l$ are the sums of the response results from the certain combination of levels of corresponding factors (each sum consists of 6 components).

Then the formula [10] is used to find the sum of squares error (SS_E):

$$SS_E = \sum_1^{n^3r} y_{ijkl}^2 - \frac{(\sum_1^{n^3} ABCD)^2}{r}. \quad [10]$$

where $ABCD$ – the sum of the replicate experiments for the DoE formulation, defined by a combination of levels of the factors **A**, **B**, **C**, and **D**.

The MS for each SS are estimated as the ratio of SS to corresponding f , where $f_A = f_B = f_C = f_D = n - 1$; $f_{AB} = f_{AD} = f_{BD} = (n - 1)^2$; and $f_{ABD} = (n - 1)^3 - (n - 1)$. F_{exp} values are determined by the general formula [11]:

$$F_{exp} = \frac{MS}{MS_E}, \quad [11]$$

where MS_E – the mean squared error (at $f_E = n^3(r - 1)$).

To interpret the experimental results and select the optimal formulation(s) for further investigation, the main effects of all individual factors and interaction effects of factor pairs on each response were graphically analyzed. The main effects were plotted as mean values from A_i , B_j , C_k , and D_l against each corresponding level for every response. The conclusion about the significance of the differences between the levels was

made taking into account the confidence interval, calculated as $\pm t_{0.05} \sqrt{\frac{MSE}{n^2}}$, where $t_{0.05}$ – Student's t-test at a 0.05 significance level. Graphical analysis of the paired interaction effects was carried out by plotting the change in response mean values of a certain level of one factor depending on the level of another factor.

Results

The experimental design matrix and results for all responses are given in Table 2.

The data of Cochran variance outlier test and ANOVA processing for each response studied are shown in Table 3.

As it can be seen from Table 3, the factors **A**, **B**, and **D** have a significant effect on all responses which were studied, while the factor C (gel-forming binder) is significant only for bulk density, Carr's index, and time of disintegration of the formulations. It was also found that pairwise interactions **AB**, **AD**, and **BD** are significant for all responses, which means that the

effect of each factor depends on the other one of the pair. The significance of the triple interaction **ABD** indicates that the effect of any pair of levels depends on the level of the third factor.

Based on statistical processing and further data interpretation, the following formulations were selected for final testing, including *in vivo* sucking time determination: **a₂b₁c₁d₃**, **a₃b₁c₁d₃**, **a₁b₁c₁d₃**, **a₂b₁c₁d₁**, **a₁b₁c₁d₁**, **a₃b₁c₁d₁**. The results are given in Table 4.

Discussion

The approach of the DoE and statistics based approaches for decision making has gained a widespread occurrence in the pharmaceutical science and drug development field; nevertheless, most reports relating to this issue describe the DoE application in the frame of optimization^(26–31). It means that the DoE method is used to choose optimal levels of quantitative parameters (independent variables) allowing to obtain best-fit responses (dependent

Table 2. Experimental design matrix and results for all responses

Formulation number	Levels of the factors				Responses									
	A	B	C	D	y ₁₁	y ₁₂	y ₂₁	y ₂₂	y ₃₁	y ₃₂	y ₄₁	y ₄₂	y ₅₁	y ₅₂
1	a ₁	b ₁	c ₁	d ₁	0.552	0.566	24.44	21.94	0.36	0.31	92.2	97.1	12.58	12.31
2	a ₁	b ₁	c ₂	d ₂	0.590	0.592	28.28	26.45	0.48	0.43	59.1	63.4	7.00	7.07
3	a ₁	b ₁	c ₃	d ₃	0.532	0.544	24.05	22.21	0.52	0.54	105.6	107.5	4.47	4.32
4	a ₁	b ₂	c ₁	d ₃	0.592	0.595	20.38	18.77	0.20	0.24	80.2	77.2	8.90	8.49
5	a ₁	b ₂	c ₂	d ₁	0.588	0.587	23.11	23.11	0.76	0.69	53.9	48.8	6.52	6.26
6	a ₁	b ₂	c ₃	d ₂	0.554	0.557	24.00	23.53	0.32	0.33	49.0	60.3	0.65	0.66
7	a ₁	b ₃	c ₁	d ₂	0.530	0.536	29.74	29.53	0.37	0.41	79.9	82.0	1.33	1.64
8	a ₁	b ₃	c ₂	d ₃	0.543	0.554	29.57	29.93	0.32	0.28	110.3	106.8	4.58	4.57
9	a ₁	b ₃	c ₃	d ₁	0.543	0.550	32.17	30.74	0.39	0.27	99.5	92.1	1.15	1.31
10	a ₂	b ₁	c ₁	d ₃	0.484	0.490	24.42	24.18	0.16	0.22	115.4	116.7	12.63	13.11
11	a ₂	b ₁	c ₂	d ₁	0.530	0.532	25.99	25.69	0.24	0.27	97.1	102.2	4.33	4.43
12	a ₂	b ₁	c ₃	d ₂	0.524	0.531	21.85	21.31	0.28	0.31	98.6	104.0	2.57	2.58
13	a ₂	b ₂	c ₁	d ₂	0.556	0.563	18.15	15.89	0.71	0.64	66.2	65.3	0.63	0.61
14	a ₂	b ₂	c ₂	d ₃	0.568	0.567	23.64	23.60	0.33	0.40	107.9	95.9	5.28	5.21
15	a ₂	b ₂	c ₃	d ₁	0.581	0.588	22.33	22.13	0.24	0.27	74.0	71.2	3.67	3.34
16	a ₂	b ₃	c ₁	d ₁	0.571	0.581	31.60	31.59	0.20	0.22	61.3	66.7	0.53	0.53
17	a ₂	b ₃	c ₂	d ₂	0.506	0.520	32.28	30.21	0.32	0.30	49.0	55.7	0.27	0.31
18	a ₂	b ₃	c ₃	d ₃	0.552	0.553	29.78	29.17	0.28	0.25	79.4	82.0	1.22	1.43
19	a ₃	b ₁	c ₁	d ₂	0.489	0.505	25.42	23.57	0.69	0.56	66.7	63.1	6.83	6.89
20	a ₃	b ₁	c ₂	d ₃	0.518	0.519	24.48	24.34	0.16	0.18	127.5	119.2	16.35	16.21
21	a ₃	b ₁	c ₃	d ₁	0.543	0.549	26.96	25.43	0.43	0.39	88.3	78.1	6.78	6.84
22	a ₃	b ₂	c ₁	d ₁	0.609	0.608	20.98	21.16	0.31	0.36	71.6	69.2	7.95	7.85
23	a ₃	b ₂	c ₂	d ₂	0.564	0.564	18.55	18.14	0.52	0.47	56.4	60.6	3.60	3.12
24	a ₃	b ₂	c ₃	d ₃	0.586	0.591	20.19	20.13	0.48	0.53	57.9	57.4	5.93	5.58
25	a ₃	b ₃	c ₁	d ₃	0.586	0.588	23.00	24.47	0.40	0.33	69.6	65.1	8.87	9.45
26	a ₃	b ₃	c ₂	d ₁	0.507	0.511	30.49	29.78	0.24	0.20	53.0	54.7	3.12	3.60
27	a ₃	b ₃	c ₃	d ₂	0.541	0.546	26.52	26.50	0.24	0.21	70.1	72.7	0.90	0.65

n = 3 for y₁₁, y₁₂, y₂₁, and y₂₂; n = 6 for y₃₁, y₃₂, y₄₁, y₄₂, y₅₁, and y₅₂

Table 3. Data of the Cochran variance outlier test and ANOVA processing ($\alpha = 0.05$)

Response	Cochran variance outlier test		ANOVA					
	C_{exp}	$C_{0.05}$	Variance source	f	SS	MS	$F_{0.05}$	F_{exp}
Bulk density (y_{11}, y_{12})	0.179	0.318	A	2	0.0026	0.0013	3.36	50.51
			B	2	0.0203	0.0101	3.36	388.52
			C	2	0.0006	0.0003	3.36	10.87
			D	2	0.0030	0.0015	3.36	57.25
			AB	4	0.0063	0.0016	2.73	60.50
			AD	4	0.0032	0.0008	2.73	31.34
			BD	4	0.0070	0.0018	2.73	66.90
			ABD	6	0.0085	0.0014	2.46	54.39
			Error	27	0.0007	$2.6 \cdot 10^{-5}$		
			Total	53	0.0523			
Carr's index (y_{21}, y_{22})	0.170	0.318	A	2	30.3907	15.1954	3.36	22.22
			B	2	623.9824	311.9912	3.36	456.20
			C	2	40.9690	20.4845	3.36	29.95
			D	2	37.1690	18.5845	3.36	27.17
			AB	4	35.1109	8.7777	2.73	12.84
			AD	4	44.0777	11.0194	2.73	16.11
			BD	4	19.5262	4.8816	2.73	7.14
			ABD	6	42.0124	7.0021	2.46	10.24
			Error	27	18.4650	0.6839		
			Total	53	891.7034			
Friability (y_{31}, y_{32})	0.208	0.318	A	2	0.0720	0.0360	3.36	23.96
			B	2	0.1835	0.0917	3.36	61.01
			C	2	0.0051	0.0025	3.36	1.69
			D	2	0.0984	0.0492	3.36	32.73
			AB	4	0.1443	0.0361	2.73	23.99
			AD	4	0.1811	0.0453	2.73	30.11
			BD	4	0.0552	0.0138	2.73	9.17
			ABD	6	0.4061	0.0677	2.46	45.01
			Error	27	0.0406	0.0015		
			Total	53	1.1863			
Resistance to crushing (y_{41}, y_{42})	0.177	0.318	A	2	1332.1471	666.0736	3.36	44.40
			B	2	6826.7119	3413.3559	3.36	227.52
			C	2	49.9136	24.9568	3.36	1.66
			D	2	6106.6480	3053.3240	3.36	203.52
			AB	4	4783.1229	1195.7807	2.73	79.71
			AD	4	399.4950	99.8738	2.73	6.66
			BD	4	903.8164	225.9541	2.73	15.06
			ABD	6	3127.3893	521.2315	2.46	34.74
			Error	27	405.0619	15.0023		
			Total	53	23934.3061			
Time of disintegration/ dissolution (y_{51}, y_{52})	0.180	0.318	A	2	93.1414	46.5707	3.36	1331.88
			B	2	293.5378	146.7689	3.36	4197.44
			C	2	132.6058	66.3029	3.36	1896.19
			D	2	221.5070	110.7535	3.36	3167.44
			AB	4	5.4066	1.3517	2.73	38.66
			AD	4	51.1883	12.7971	2.73	365.98
			BD	4	24.3558	6.0889	2.73	174.14
			ABD	6	77.3540	12.8923	2.46	368.71
			Error	27	0.9441	0.0350		
			Total	53	900.0408			

Variance sources, the contribution of which to the sum of squares is insignificant, are highlighted in gray.

Table 4. The results of final testing the selected formulations

Parameters tested	Formulation code			
	$a_2b_1c_1d_3$	$a_3b_1c_1d_3$	$a_1b_1c_1d_3$	$a_2b_1c_1d_1$
Visible defects of tablets	No	No	No	No
Bulk density, g/cm ³	0.491 ± 0.025	0.543 ± 0.018	0.541 ± 0.009	0.537 ± 0.006
Carr's index, %	24.17 ± 1.20	19.03 ± 1.79	18.74 ± 0.44	24.22 ± 0.90
Friability, %	0.17 ± 0.01	0.20 ± 0.01	0.28 ± 0.02	0.22 ± 0.01
Resistance to crushing, N	120.8 ± 13.2	126.1 ± 6.5	107.2 ± 8.1	106.6 ± 5.5
Disintegration time, min	13.11 ± 3.08	23.82 ± 0.22	17.67 ± 0.73	8.09 ± 2.17
In vivo sucking time	7.35 ± 0.94	12.91 ± 2.67	9.82 ± 1.44	4.53 ± 0.72
Taste characteristics	Slightly sweetish with a slightly bitter aftertaste	Sweetish, with a neutral aftertaste	Slightly sweetish with a neutral aftertaste	Sweetish, with a slightly bitter aftertaste

Values are expressed as means ± confidence interval ($\alpha = 0.05$).

variables). In the case of formulation development study, independent variables may be different concentrations of selected excipients, whereas dependent ones – drug quality attributes. On the other hand, for the majority of pharmaceutical excipients, there are data, available in the literature or provided by manufacturers, on recommended excipient dosing for various functional performances. So, very often it is the choice of excipient types that becomes a real challenge. In this regard, it is worthy to note that DoE and data statistic processing methods are applicable not only for quantitative decisions (i.e., as optimization tool) but also for choosing qualitative factors, including the types of excipients. For this purpose, the ANOVA method is best fitted as statistically valid decision-making on the choice of qualitative factors.

Traditionally two-dimensional Latin square designs are the most popular for ANOVA-based choice of qualitative variables, which is related to the simplicity of such model statistics processing and a small number of experimental runs. Nevertheless, with Latin square it is not possible to estimate any interaction terms, which may be of great interest considering pharmaceutical preparation as a complex interacting system. To overcome this drawback Latin square can be extended to three or more dimensions to obtain Latin cube or Latin hypercube designs and in this case, two-factor interactions are statistically interpreted. In this work, we chose a fractional factorial Latin cube design with two replications in order to assess the effect of four factors varying at three levels, including the main effects of each factor (individually) and interaction effects of their paired combinations.

A pre-step of every formulation development study is the selection of the factors which effect to be studied. When solving this issue, first of all, we considered the principal technological feature of compressed lozenges – non-disintegrating and slow-dissolving behavior in liquid media. Obviously, this can be achieved by strong binding powder particles with each other, which prevents the rapid penetration and spread of liquid in the tablets. As a rule, the most

effective binding results from the wet granulation tableting method; however, in comparison with direct compression, it involves more stages and additional equipment units and, consequently, consumes more time and costs. Therefore, the excipients for direct compression with a declared good compression profile were selected for the study. For instance, spray-dried mannitol (Mannogem® EZ), lactose co-processed with microcrystalline cellulose (Cellactose® 80), and isomalt (GalenIQ™ 721) were selected as directly compressible fillers with a pleasant taste. In order to attain good coupling of powder particles, the dry binders, such as Plasdone™ S-630, Kollidon® 90 F, and Avicel® PH-101, were included in the DoE plan. The necessity for the addition of another binder type – gel-forming was also investigated. Such excipients were assumed to prolong dissolution by forming a viscous layer around the tablet and slowing down its disintegration. This assumption is supported by the fact that some commercially available compressed lozenges contain gel-forming excipients such as natural gums and cellulose derivatives. In view of this, we compared the effect of Metolose 90SH-4000SR, guar gum, and the absence of a gel-forming binder. And the last group of excipients that were chosen for the study is the substances improving powder flow (and they also affect tablet disintegration/dissolution primarily due to their hydrophobic nature) – PRUV®, Neusilin® US2, and Compritol® 888 CG ATO.

The inclusion of replications in the DoE makes it necessary to evaluate the reproducibility of the results obtained in different replicas before processing the experimental data. In this paper, reproducibility means within-laboratory consistency, and since all experiments in both replicas were performed on the same equipment and by the same operators, the source of possible inconsistency is only random errors. For examining the within-laboratory consistency, Cochran's test is recommended by ISO 5725-2. Comparison of the experimental Cochran's C value (C_{exp}) with the tabulated critical value ($C_{0.05}$) for each response (see Table 3 in the Results section) indicates the consistency of the results obtained.

Taking into account the primary technological goal in the formulation development of compressed lozenges (i.e., slow-dissolving behavior), the experimental data of the disintegration test were chosen as a starting point for the interpretation. Figure 1 shows the histogram of factor main effects on the mean values of disintegration time (calculated from A_i , B_j , C_k , and D_l) (I) and plots of paired interaction effects (II).

From Figure 1-I it can be seen that among all factors studied, the most prominent difference between the levels occurs for the dry binder types. In the case of compressed lozenges, *in vitro* disintegration time of about 10–20 min is considered as appropriate, which is supposed to correspond to around 5–10 min *in vivo* sucking time³². Hence, Plasdone™ S-630 (b_1) is the most effective dry binder, irrespectively of the other factor levels. The latter becomes clear from b_j -level plots, which for all a and d levels give higher response mean values (Fig. 1-II). The preference rank order for the dry binders can be expressed as Plasdone™ S-630 (b_1) > Kollidon® 90 F (b_2) > Avicel® PH-101 (b_3). Therefore Plasdone™ S-630 is chosen as an undoubted favorite for the formulation being developed, while when choosing the levels of factors A and D , the contribution of their main and interaction effects to all responses was taken into account. For instance, preference rank orders for these factors by the disintegration test are GalenIQ™ 721 (a_3) > Mannogem® EZ (a_1) > Cellactose® 80 (a_2) and Compritol® 888 CG ATO (d_3) > PRUV® (d_1) > Neusilin® US2 (d_2) (Fig. 1-I). Assessment of AD level interaction revealed that the best three filler–antifricition excipient combinations are ranked as a_3d_3 > a_1d_1 = a_2d_3 (Fig. 1-II). As for factor C , the results that we obtained are opposite to those expected: the

longer disintegration time mean values are found in the absence of a gel-forming binder (c_1). Since the function of the factor C excipients is supposed to be the prolongation of tablet disintegration time, these results indicate that the addition of both hypromellose (c_2) and guar gum (c_3) is useless. Besides, according to modern tendencies in the pharmaceutical industry, every excipient in drug formulation is associated with certain risks; therefore, elimination of excipients that have not proved their functionality also reduces the overall risk for the developed drug³³. Probably, the inefficiency of gel-forming binders may be explained that when these excipients are used in amounts of 3% their swelling rather promotes tablet expansion and water penetration into it than contribute to forming of gel viscous enough to inhibit the disintegration process. Accordingly, the conclusion about the uselessness of the gel-forming binders is only valid for 3% amounts, which, in fact, represents the limitation of the DoE applied in choosing qualitative factors without varying their quantities. Nevertheless, it is decided that there is no need for the additional investigation of other amounts or types of such excipients because the set goal is achievable without them.

The final formulation of compressed lozenges must meet not only certain biopharmaceutical requirements on its release behavior but also be manufacturable. Therefore the bulk density and Carr's index, reflecting technological properties of the tablet blend, as well as mechanical strength characteristics of compressed tablets, were included in the DoE. So, hereinbelow the data obtained from the analysis of these responses are discussed.

The bulk density of a tablet blend determines the required volume of the tablet machine die cavity




Fig. 1. Effects of the factor levels on the mean values of tablet disintegration/dissolution time: I – main factor effects, II – effects of paired interactions

since die filling during compression is a volumetric process. Most pharmaceutical powders have bulk densities in the range of 0.1–0.7 g/cm³, and values closer to the upper edge of this range are preferable as they facilitate dosing the active ingredient in patient acceptably sized dosage forms³⁴). According to the bulk density mean values Plasdone™ S-630 (**b**₁), previously chosen in the disintegration test as a favorite among dry binders, ranks last significantly losing to Kollidon® 90 F (**b**₂) and to a lesser extent – Avicel® PH-101 (**b**₃) (Fig. 2-I). However, if consider level interactions, **a**₁**b**₁ gives higher mean values than all **a**₁**b**₃ combinations (Fig. 2-II). As for factor **D** levels, PRUV® (**d**₁) appears to be the best both by main factor effects (Fig. 2-I) and among **b**₁**d**₁ combinations (Fig. 2-II), while Compritol® 888 CG ATO (**d**₃) is the best antifriction excipient for GalenIQ™ 721 (**a**₃) (i.e., **a**₃**d**₃ combination). For factor **C** the absence of a gel-forming binder (**c**₁) and the use of guar gum (**c**₂) are equally the best levels.

Carr's index calculated from the bulk and tapped density are a pharmacopoeial parameter used to characterize powder flowability. Lower Carr's indices evidence on the better flowability of the tablet blend samples²). From this point of view, Plasdone™ S-630 (**b**₁) ranks second after Kollidon® 90 F (**b**₂), which is the leader among dry binders (Fig. 3-I) and no matter what **a**_i or **d**_i level it is combined with (Fig. 3-II). Combinations of Plasdone™ S-630 (**b**₁) also do not differ dramatically. However, **a**₂**b**₁ and **b**₁**d**₃ may be regarded as those with the lowest response mean values. Preference rank orders by Carr's index for factors **A** and **D** are expressed as GalenIQ™ 721 (**a**₃) > Cellactose® 80 (**a**₂) = Mannogem® EZ (**a**₁) and Compritol® 888 CG ATO (**d**₃) > Neusilin® US2 (**d**₂) = PRUV® (**d**₁), respectively (Fig.

3-I). **AD** combinations with the lowest mean values of Carr's index are **a**₃**d**₃, **a**₃**d**₂, and **a**₂**d**₂ (Fig. 3-II).

Friability is the measure of the tablet's resistance to the subsequent process condition and transportation; lower friability values indicate better mechanical properties of the tablets³⁵). According to pharmacopoeial requirements friability of tablets should not exceed 1%²). As it comes from Figure 4-I preference rank orders for levels of the factors **A**, **B**, and **D** can be described as Cellactose® 80 (**a**₂) > GalenIQ™ 721 (**a**₃) > Mannogem® EZ (**a**₁), Avicel® PH-101 (**b**₃) > Plasdone™ S-630 (**b**₁) > Kollidon® 90 F (**b**₂), and Compritol® 888 CG ATO (**d**₃) = PRUV® (**d**₁) > Neusilin® US2 (**d**₂), respectively, while factor **C** is insignificant. Interestingly, when comparing the preference rank order of factor **B** levels with that one obtained for Carr's index, it can be easily found that they are exactly opposite. This means that the dry binder Kollidon® 90 F (**b**₂) giving the best Carr's index results in the highest friability, and inversely, the loser at Carr's index test Avicel® PH-101 (**b**₃) provide the lowest tablet friability. This can be understood as follows: flowability, and hence Carr's index, is better when interparticle adhesion is less; in turn, greater particle adhesive capacity leads to less friability, i.e. the ability of powder particles to detach from the tablet surface under mechanical stress. In general, the more compressible is the material the less flowable it will be; therefore, one of the main challenges in tablet formulation development is to achieve good flowability of a tablet blend with good mechanical properties of tablets³⁶). It should also be focused on higher friability values obtained in testing formulations with Neusilin® US2 (**d**₂). Obviously, this is related to visible surface defects such as chipping and partial capping,




Fig. 2. Effects of the factor levels on the mean values of tablet blend bulk density: I – main factor effects, II – effects of paired interactions

detected for most d_2 -formulations but not for d_1 or d_3 levels. Based on this, we can conclude that despite Neusilin® US2 is effective enough as a glidant (which is confirmed by Carr's index testing), it has insufficient anti-adherence activity, i.e., in the amount of 2%, it is not able to prevent the adhesion of the tablet blend to tablet machine punches. On the other hand, an

increase in the content of Neusilin® US2 in the tablets may negatively affect the taste of the formulation being developed. As for the interaction of factors, the best combinations of Plasdone™ S-630 (b_1) in terms of friability turned out to be a_2b_1 and b_1d_3 , while among AD combinations, the lowest mean values are obtained from a_2d_1 , a_2d_3 , and a_3d_1 (Fig. 4-II).




Fig. 3. Effects of the factor levels on the mean values of Carr's index: I – main factor effects, II – effects of paired interactions




Fig. 4. Effects of the factor levels on the mean values of tablet friability: I – main factor effects, II – effects of paired interactions

Resistance to crushing is another pharmacopoeial technical parameter used to evaluate tablet mechanical properties. Along with friability, it indicates the ability of tablets to be processed (in the case of coating), packed, and transported without fracturing. However, from the point of view that this parameter shows binding efficacy of powder particles, it is also linked to the behavior of compressed dosage units in liquid media, i.e., disintegration rate. Consequently, for compressed lozenges, values of resistance to crushing greater than those for traditional tablets should be achieved. As it comes from Figure 5-I, the most contribution in tablet resistance to crushing is made by Plasdone™ S-630 (b_1) and Compritol® 888 CG ATO (d_3). Avicel® PH-101 (b_3), a leader among dry binders in friability test, ranks second. Differences in dry binder rank orders may be linked to different predominating binding mechanisms of these excipients. Probably, the binding ability of Plasdone™ S-630 (b_1), a water-soluble copolymer, to a great extent is facilitated by moisture that releases from powders during the compression process and enforces the formation of hydrogen bond bridges between particles. Taking into account the relatively low moisture content of pharmaceutical powders, moisture-mediated binding appears to be more effective inside the tablets than on their surface, so it contributes more to crushing resistance than friability. At the same time, Avicel® PH-101 (b_3), a water-insoluble excipient, is known for its excellent plastic deformability under pressure, which increases the area of both surface and internal particle-particle contact and cohesion³⁷). Among level combinations,

the most positive effects on tablet crushing resistance are observed for b_1d_3 , a_2b_1 , a_2d_3 , and a_1d_3 (Fig. 5-II).

Based on described above experimental data analysis, four formulations are selected for additional investigation: $a_2b_1c_1d_3$, $a_3b_1c_1d_3$, $a_1b_1c_1d_3$, and $a_2b_1c_1d_1$. It should be noted that we considered only formulations with levels b_1 and c_1 for factors **B** and **C**, respectively, and excluded formulations with level d_2 for factor **D**. From the results given in Table 4 (see "Results" section), formulation $a_3b_1c_1d_3$ is chosen as that one providing sufficient pharmaco-technical properties of tablet blend, mechanical characteristics of compressed tablets, their non-disintegrating, slow-dissolving behavior, as well as pleasant taste and mouthfeel during sucking. The composition of the chosen formulation of compressed lozenges is presented in Table 5.

Conclusions

This study has demonstrated the opportunity for DoE application in the formulation development as a tool to select types of excipients providing best-fit characteristics of the developed preparation. In order to develop anti-stress compressed lozenges containing glycine and magnesium citrate as active ingredients, 27 experimental formulations according to fractional factorial Latin cube design were tested on such parameters as bulk density, Carr's index, friability, resistance to crushing, and tablet *in vitro* disintegration time. The latter was considered as the main attribute responsible for providing the preparation of its specific




Fig. 5. Effects of the factor levels on the mean values of tablet resistance to crushing: I – main factor effects, II – effects of paired interactions

Table 5. The composition of the chosen formulation of compressed lozenges

Name of ingredient	Function in the formulation	Amount per tablet, mg
Glycine	Active pharmaceutical ingredient	100
Magnesium citrate	Active pharmaceutical ingredient	250
Isomalt (GalenIQ™ 721)	Filler	90
Copovidone (Plasdone™ S-630)	Dry binder	50
Glyceryl behenate (Compritol® 888 CG ATO)	Antifriction excipient	10
Total tablet weight		500

release properties – slow dissolution during sucking in the oral cavity. Using the ANOVA approach for statistical processing, the following excipients were selected to be incorporated in the final formulation: isomalt GalenIQ™ 721 (tablet filler), Plasdone™ S-630 copovidone (dry binder), and glyceryl behenate Compritol® 888 CG ATO (antifriction excipient). Data processing by ANOVA also allowed revealing excipient interaction effects on the parameters studied, which may be useful in similar formulation development studies.

Conflict of interest: none.

References

1. Zhang H., Zhang J., Streisand J. B. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. *Clin Pharmacokinet.* 2002; 41(9), 661–680.
2. Council of Europe. European Pharmacopoeia, 10th edition, Strasbourg: Council of Europe, 2019.
3. Ashraf M., Sayeed V. A. Considerations in developing sublingual tablets – an overview. *Pharm. Technol.* 2014; 38(11), 38–47.
4. Dawson D. V., Drake D. R., Hill J. R., Brogden K. A., Fischer C. L., Wertz P. W. Organization, barrier function and antimicrobial lipids of the oral mucosa. *Int. J. Cosmet. Sci.* 2013; 35(3), 220–223.
5. Squier C. A. The permeability of oral mucosa. *Crit. Rev. Oral. Biol. Med.* 1991; 2(1), 13–32.
6. Shinkar D. M., Dhake A. S., Setty C. M. Drug delivery from the oral cavity: a focus on mucoadhesive buccal drug delivery systems. *PDA J. Pharm. Sci. Technol.* 2012; 66(5), 466–500.
7. Fonseca-Santos B., Chorilli M. An overview of polymeric dosage forms in buccal drug delivery: State of art, design of formulations and their *in vivo* performance evaluation. *Mater. Sci. Eng. C Mater. Biol. Appl.* 2018; 86, 129–143.
8. Maheshwari R., Jain V., Ansari R., Mahajan S. C., Joshi G. A review on lozenges. *Br. Biomed. Bull.* 2013; 1, 35–43.
9. Majekodunmi S. O. A review on lozenges. *American Journal of Medicine and Medical Sciences* 2015; 5(2), 99–104.
10. Uvnäs-Moberg K., Prime D. K. Oxytocin effects in mothers and infants during breastfeeding. *Infant.* 2013; 9(6), 201–206.
11. Uvnäs-Moberg K., Handlin L., Petersson M. Self-soothing behaviors with particular reference to oxytocin release induced by non-noxious sensory stimulation. *Front. Psychol.* 2015; 5, 1529.
12. Guzmán Y. F., Tronson N. C., Jovasevic V., Sato K., Guadea A. L., Mizukami H., Nishimori K., Radulovic J. Fear-enhancing effects of septal oxytocin receptors. *Nat. Neurosci.* 2013; 16(9), 1185–1187.
13. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., Gruppe H., Mattay V. S., Gallhofer B., Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. *J. Neurosci.* 2005; 25(49), 11489–11493.
14. Gundersen R. Y., Vaagenes P., Breivik T., Fonnum F., Opstad P. K. Glycine – an important neurotransmitter and cytoprotective agent. *Acta Anaesthesiol. Scand.* 2005; 49, 1108–1116.
15. Petrat F., Boengler K., Schulz R., de Groot H. Glycine, a simple physiological compound protecting by yet puzzling mechanism(s) against ischaemia-reperfusion injury: current knowledge. *Br. J. Pharmacol.* 2012; 165(7), 2059–2072.
16. Kawai N., Sakai N., Okuro M., Karakawa S., Tsuneyoshi Y., Kawasaki N., Takeda T., Bannai M., Nishino S. The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus. *Neuropsychopharmacology* 2015; 40(6), 1405–1416.
17. Bannai M., Kawai N. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. *J. Pharmacol. Sci.* 2012; 118(2), 145–148.
18. Gusev E. I., Skvortsova V. I., Dambinova S. A., Raevskiy K. S., Alekseev A. A., Bashkatova V. G., Kovalenko A. V., Kudrin V. S., Yakovleva E. V. Neuroprotective effects of glycine for therapy of acute ischaemic stroke. *Cerebrovasc. Dis.* 2000; 10(1), 49–60.
19. El Hafidi M., Pérez I., Baños G. Is glycine effective against elevated blood pressure? *Curr. Opin. Clin. Nutr. Metab. Care* 2006; 9(1), 26–31.
20. Imtiaz S., Ikram H., Ayaz M., Qadir M. I., Muhammad S. A. Effect of glycine: Studying memory and behavioral changes in mice. *Pak. J. Pharm. Sci.* 2018; 31(5), 1943–1949.
21. Razak M. A., Begum P. S., Viswanath B., Rajagopal S. Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. *Oxid Med. Cell Longev.* 2017; 2017, 1716701.
22. Yakovenko O., Ruban O., Devyatkina N., Devyatkina T. Study of the stress-protective effect of the combination of glycine with magnesium citrate. *Norwegian Journal*

- of development of the International Science 2020; 48, 52–58.
23. **Sartori S. B., Whittle N., Hetzenauer A., Singewald N.** Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. *Neuropharmacology* 2012; 62(1), 304–312.
 24. **Tarasov E. A., Blinov D. V., Zimovina U. V., Sandakova E. A.** Magnesium deficiency and stress: Issues of their relationship, diagnostic tests, and approaches to therapy. *Ter. Arkh.* 2015; 87(9), 114–122. Russian.
 25. **Hroshovyi T. A., Martsenyuk V. P., Kucherenko L. I., Vronska L. V., Huryeyeva S. M.** Mathematical planning of experiment in pharmacy. Ternopil, Ukraine: Ternopil State Medical University 2008. Ukrainian.
 26. **Singh B., Kumar R., Ahuja N.** Optimizing drug delivery systems using systematic “design of experiments.” Part I: fundamental aspects. *Crit. Rev. Ther. Drug Carrier Syst.* 2005; 22(1), 27–105.
 27. **Dennison T. J., Smith J., Hofmann M. P., Bland C. E., Badhan R. K., Al-Khattawi A., Mohammed A. R.** Design of Experiments to Study the Impact of Process Parameters on Droplet Size and Development of Non-Invasive Imaging Techniques in Tablet Coating. *PLoS One* 2016; 11(8), e0157267.
 28. **Politis S. N., Colombo P., Colombo G., Rekkas D. M.** Design of experiments (DoE) in pharmaceutical development. *Drug Dev. Ind. Pharm.* 2017; 43(6), 889–901.
 29. **Fukuda I. M., Pinto C. F. F., Moreira C. S., Saviano A. M., Lourenço F. R.** Design of Experiments (DoE) applied to Pharmaceutical and Analytical Quality by Design (QbD). *Braz. J. Pharm. Sci.* 2018; 54(Special), e01006.
 30. **Saydam M., Takka S.** Development and *in vitro* evaluation of pH-independent release matrix tablet of weakly acidic drug valsartan using quality by design tools. *Drug Dev. Ind. Pharm.* 2018; 44(12), 1905–1917.
 31. **Wang Q., Wong C. H., Chan H. Y. E., Lee W. Y., Zuo Z.** Statistical Design of Experiment (DoE) based development and optimization of DB213 *in situ* thermosensitive gel for intranasal delivery. *Int. J. Pharm.* 2018; 539(1–2), 50–57.
 32. **Tietz K., Gutknecht S. I., Klein S.** Bioequivalence of locally acting lozenges: Evaluation of critical *in vivo* parameters and first steps towards a bio-predictive *in vitro* test method. *Eur. J. Pharm. Biopharm.* 2018; 123, 71–83.
 33. **Ruban O., Pidpruzhnykov Y., Kolisnyk T.** Excipient risk assessment: possible approaches to assessing the risk associated with excipient function. *J. Pharm. Investig.* 2018; 48, 421–429.
 34. **Hancock B. C., Colvin J. T., Mullarney M. P., Zinchuk A. V.** The relative densities of pharmaceutical powders, blends, dry granulations, and immediate-release tablets. *Pharm Technol.* 2003; 27(4), 64–80.
 35. **Pandeya A., Puri V. M.** Relationships between tablet physical quality parameters and granulated powder properties: feasibility study. *Particul. Sci. Technol.* 2012; 30(5), 482–496.
 36. **Sarraguça M. C., Cruz A. V., Soares S. O., Amaral H. R., Costa P. C., Lopes J. A.** Determination of flow properties of pharmaceutical powders by near infrared spectroscopy. *J. Pharm. Biomed. Anal.* 2010; 52, 484–492.
 37. **Paul S., Sun C. C.** Dependence of Friability on Tablet Mechanical Properties and a Predictive Approach for Binary Mixtures. *Pharm. Res.* 2017; 34, 2901–2909.